REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C. — Aug. 25, 2022 — Kriya Therapeutics, Inc., a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, announced today that it has appointed Curt Herberts, M.B.S., as President and Chief Operating Officer. Herberts will oversee all general and administrative functions at Kriya.
“Curt’s extensive experience building successful biotech companies will be a great asset for Kriya, as we expand our operations and capabilities for developing gene therapies to treat patients in need,” said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya. “Curt and I will be working in close partnership to build value for patients, investors, and employees.”
Herberts joins Kriya from Senti Biosciences, Inc., where he was Chief Financial Officer and Chief Business Officer from 2018 to 2021, and Chief Operating Officer from 2021 to 2022. Prior to joining Senti, Herberts held various positions at Sangamo Therapeutics including as the company’s Chief Business Officer, as well as at Campbell Alliance Group, a leading management consulting firm specializing in the life science industry. Herberts earned his B.A. from Stanford University in human biology, and his Master of Business and Science from the Keck Graduate Institute of Applied Life Sciences.
“I am excited to join a company with a fully-integrated gene therapy engine that has the potential to develop a robust pipeline of therapies to treat a wide range of diseases,” Herberts said. “I’m looking forward to helping the company lead the industry in ushering in a new era of innovative gene therapies for a broad range of therapeutic areas.”
Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed, and manufactured, improving speed to market and delivering significant reductions in cost. The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in ophthalmology, oncology, rare disease, and chronic disease. Kriya is backed by leading life sciences and technology investors, and has core operations in Silicon Valley, California and Research Triangle Park, North Carolina.
For more information, please visit www.kriyatx.com and follow on LinkedIn and Twitter.
Ryan Flinn, VP, Head of Communications
Kriya Therapeutics, Inc.